Introduction
============

Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in developed countries \[[@r1]\]. AMD involves the progressive loss of photoreceptor cells from the macular region of the retina, resulting in impaired vision and, in advanced stages, blindness. At least three cell layers undergo changes in AMD, including the photoreceptor cells, retinal pigment epithelium (RPE), and choriocapillaris. The RPE regulates the activities of the photoreceptor cells and choriocapillaris. For example, RPE cells actively phagocytose photoreceptor cell outer segments, recycle vitamin A, shuttle debris from the photoreceptor cells to the bloodstream, and import glucose, oxygen, and other components to accommodate the high metabolic demands of the retina \[[@r2]\], in addition to providing trophic support to the choriocapillaris \[[@r3],[@r4]\]. The choroid serves as a high-volume transportation courier, delivering nutrients to the RPE and accepting waste products for further processing elsewhere in the body. The preclinical and early stages of AMD are recognizable by increased formation of lipid-rich sub-RPE deposits termed drusen and altered RPE pigmentation \[[@r5],[@r6]\].

The photoreceptor cells, RPE, and choriocapillaris endothelial cells form an interdependent complex. Injury or dysfunction in any of these layers leads to loss of the other two in several chorioretinal diseases. A more complete understanding of the early sequelae of events in AMD is necessary to guide new therapies. Numerous interdependent biologic processes have been implicated in the pathogenesis of AMD, including increased activity of the complement cascade, infiltration of cells mediating inflammatory responses, increased oxidative stress, and altered lipid metabolism \[[@r7],[@r8]\]. Although RPE cells are typically viewed as the primary cells affected in AMD, changes in the microvasculature of the choroid (choriocapillaris) have also been reported in association with drusen, including dropout of vessels \[[@r9],[@r10]\] and decreased blood flow \[[@r11]\]. In a subset of advanced AMD cases, choroidal neovascular membranes (CNVs) form as blood vessels from the choroid breach the RPE and proliferate either beneath the RPE or in the sub-retinal space. Expression of vascular endothelial growth factor (VEGF), a marker of hypoxia, has been implicated in the formation of CNVs \[[@r12]\]. In current medical practice, only after CNVs have appeared and photoreceptor cell death has occurred can therapeutic measures be taken to slow further vision loss \[[@r13]\].

Despite considerable progress in unraveling genetic risk factors for AMD, major challenges remain. The relationships between the biologic processes remain uncertain, and the initial molecular conditions driving development of AMD are poorly understood. Evaluating gene expression in early AMD, intermediate AMD, and advanced AMD is one approach to advancing exploration of these problems. The first large-scale study of gene expression in the AMD-affected retina and RPE and choroid tissue identified changes between various stages of AMD, including apoptotic and neovascular pathways in advanced AMD \[[@r14]\]. As part of a study examining the relationship between AMD and gene methylation, Hunter and colleagues examined gene expression in AMD and normal samples \[[@r15]\]. They found that expression of glutathione S-transferase isoform mu1 (*GSTM1*) and mu5 (GSTM5), antioxidant isoenzymes, was reduced in the RPE and choroid of eyes affected by AMD compared to control eyes; this reduction was correlated with hypermethylation of the GSTM1 promoter \[[@r15]\]. However, only two of the samples were classified as early AMD, and analysis was performed without respect to AMD grade.

To further investigate the molecular events initiating AMD, we evaluated gene expression in early AMD and normal RPE and choroid tissues using exon-based microarrays (Affymetrix). Our analysis identified a statistically significant decrease in expression of endothelial genes in early AMD with preservation of RPE-specific transcripts, suggesting that vessel loss or dedifferentiation may precede advanced damage in AMD.

Methods
=======

Tissue acquisition
------------------

Donor eyes were obtained through the Iowa Lions Eye Bank (Iowa City, IA) after receiving informed consent in accordance with the tenets of the Declaration of Helsinki. Donor age, sex, cause of death, and diagnostic status are listed in [Table 1](#t1){ref-type="table"}. Eyes were dissected, and 6 mm punches were taken from the macula, centered on the fovea centralis. Macular RPE and choroid were separated from the neural retina, flash frozen in liquid nitrogen, and stored at −80 °C. The neural retina was used for separate experiments. In this manner, RNA was stabilized within 4 h of death. RNA was extracted from the frozen RPE and choroids using a commercially available kit (RNeasy Mini Kit; Qiagen, Valencia, CA).

###### Donor information.

  Sample    Batch   Gender   CFH genotype   Age   Cause of death             Age-related maculopathy
  --------- ------- -------- -------------- ----- -------------------------- -------------------------------------------------------------
  ARM1      A       F        HY             78    Coronary artery disease    RPE changes
  ARM2      A       F        HY             80    Intracerebral hemorrhage   RPE changes
  ARM3      A       M        HY             90    Respiratory failure        Macular drusen
  ARM4      A       F        HY             91    Pneumonia                  Macular drusen
  ARM5      A       F        YY             91    Not available              RPE changes; neovascular membrane in contralateral eye
  ARM6      A       M        HH             78    Respiratory failure        RPE changes
  ARM7      B       F        YY             81    Ischemic bowel             RPE changes
  ARM8      B       M        HH             92    Pneumonia                  Numerous large drusen, no atrophy or exudate
  ARM9      B       M        HH             77    Not available              RPE changes
  CTRL1     B       M        HY             93    Cardiac arrest             Normal fundus exam \<2 years
  CTRL2     A       M        YY             83    Pneumonia                  Normal fundus exam \<2 years; large cup to disc ratio
  CTRL3\*   B       M        HY             84    Subdural hematoma          Normal fundus exam \>2 years
  CTRL4     B       F        HY             77    Not available              Normal fundus exam but old records; normal gross appearance
  CTRL5     A       M        YY             81    Respiratory failure        Normal fundus exam \<2 years
  CTRL6     A       F        HH             87    Aortic stenosis            Normal fundus exam \<2 years
  CTRL7     A       M        HY             77    Renal failure              Normal fundus exam \<2 years
  CTRL8     B       F        YY             83    Not available              Normal fundus exam \<2 years
  CTRL9\*   A       M        HY             77    Brain tumor                Normal fundus exam \<2 years

Asterisks (\*) denote samples that did not pass quality control metrics. Batch indicates the batch of array processing. RPE changes refer to regions where RPE is depigmented or hypopigmented \[[@r32]\].

*CFH* risk-allele genotyping
----------------------------

To characterize how the risk allele in complement factor H (*CFH*; single nucleotide polymorphism \[SNP\] [rs1061170](http://www.ncbi.nlm.nih.gov/snp/?term=rs1061170)) affects gene expression in the RPE and choroid, genotyping was performed on DNA from either whole blood (collected in EDTA-coated tubes) or extraocular muscle. DNA was isolated using established methods with the Gentra system (Qiagen, Valencia, CA) or the Qiagen DNeasy Blood & Tissue Kit, for blood and muscle, respectively. Genotyping of this polymorphism was performed using TaqMan predesigned SNP genotyping assays (Applied Biosystems) in a high-throughput system (Fluidigm, San Francisco, CA).

Microarray processing
---------------------

Exon expression levels of the RPE and choroid RNA were determined using Affymetrix GeneChip Human Exon 1.0 ST arrays processed in two batches at the University of Iowa DNA Facility. Samples were used essentially as previously described \[[@r16]\]. Briefly, single primer isothermal amplification was used to convert 25 ng total RNA to cDNA with the WT-Ovation Pico RNA Amplification System (NuGEN Technologies, San Carlos, CA). The resulting cDNA was purified using a Qiagen QIAquick PCR Purification column, converted to sense target (ST)-cDNA using the WT-Ovation Exon Module v1 (NuGEN Technologies), and purified once more. ST-cDNA was then fragmented (85 nt mean length), and the NuGEN FL-Ovation cDNA Biotin Module, v2 (NuGEN Technologies) was used to biotin-label the fragments according to the manufacturer's guidelines. This product was combined with Affymetrix eukaryotic hybridization buffer (Affymetrix, Santa Clara, CA) and hybridized to Affymetrix Human Exon 1.0 ST arrays (Affymetrix). An Affymetrix Model 3000 scanner with 7G upgrade was used to scan the arrays. Data were collected with GeneChip operating software (ver. 1.4; Affymetrix) and saved as CEL files.

Microarray analysis
-------------------

### Preprocessing, expression analysis, and quality control

To assess differential expression and alternative splicing, CEL files were normalized by robust multiarray average (RMA) \[[@r17]\] to facilitate comparisons across arrays using AltAnalyze (ver. 2.0.7 beta) with gene and transcript data from the Ensembl 65 database and human genome build Hg19 \[[@r18]\]. RMA, a common algorithm for processing microarray data, corrects for background fluorescence, normalizes data for comparison between arrays, and produces log~2~-transformed estimates of probeset expression. Technical variation among microarrays is well known and often arises when arrays are processed in separate batches (i.e., prepared by different people, on different days, etc.) \[[@r19]\]. To address this issue in our data set, initial probeset-level expression estimates were corrected for batch effects while preserving AMD status, CFH genotype, and sex covariates using the ComBat algorithm \[[@r20]\]. ComBat removes batch effects more effectively than several other procedures \[[@r21]\]. The batch-corrected data were reimported into AltAnalyze and processed as follows: masking of cross-hybridizing probesets; filtering probesets expressed below non-log level (i.e., expression intensity before log~2~ transformation) of 70; gene-level differential expression using a moderated *t* test; and computation of false discovery rate (FDR) adjusted p values to account for multiple hypothesis testing correction \[[@r22]\]. Heatmap generation and hierarchical clustering were performed using the R statistical software (ver. 3.0.0) \[[@r23]\]. To cluster genes based on the similarity of the expression pattern across samples, we used a Pearson-based distance metric (1 minus Pearson's correlation coefficient) \[[@r24]\]. To assess alternative splicing, the splicing index and MIDAS \[[@r25]\] procedures in AltAnalyze were used. Putatively alternatively spliced transcripts were visualized using DomainGraph (ver. 3.0) \[[@r18]\], a plugin for Cytoscape (ver. 2.8.1) \[[@r26]\]. Quality control metrics, including distance between arrays and comparison of array intensity distributions, were calculated using the arrayQualityMetrics package (ver. 3.16.0) \[[@r27]\] for R. After outlying arrays were removed, the final AltAnalyze results were recomputed.

Gene set analysis
-----------------

The Ensembl BioMart tool was used to map identifiers from previous gene expression studies to Ensembl IDs \[[@r28]\]. Gene set enrichment analysis (GSEA; ver. 14) \[[@r29]\] implemented with GenePattern (ver. 3.6.0) \[[@r30]\] was used to evaluate the overrepresentation of custom gene sets with AMD or control samples. For GSEA, phenotype permutation was performed using 1,000 permutations and two gene sets, an RPE-specific set and an endothelium-associated set, compiled based on literature search. Annotation of differentially expressed genes was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) Functional Annotation Tools with default parameters \[[@r31]\].

Results
=======

Quality control
---------------

We defined early AMD as RPE changes (depigmentation or hypopigmentation) and/or macular drusen without geographic atrophy (GA) or CNV \[[@r32]\] as determined by chart review. Eyes with CNV or geographic atrophy were excluded. Since early AMD was classified in the donors by ophthalmoscopy, completely ruling out a rare event such as occult CNV is impossible in the early AMD samples. With the exception of one donor who later did not pass quality control, all unaffected control donors were required to have had a normal fundus exam within two years of death. Based on these criteria, nine samples were classified as early AMD (designated ARM1-9) and nine samples were classified as controls (designated CTRL1-9; [Table 1](#t1){ref-type="table"}). To assess the statistical equivalence of donor ages in each group, we performed Welch's two-sample *t* test, which gave a p value of 0.54. The mean RNA integrity numbers for samples processed in batch A was 6.76 (standard deviation \[SD\] 0.34) and for batch B was 6.22 (SD 0.59; [Table 1](#t1){ref-type="table"}). Following normalization in AltAnalyze ([Figure 1](#f1){ref-type="fig"}), samples CTRL3 and CTRL9 were flagged as potential outliers by arrayQualityMetrics analysis \[[@r27]\] based on their sum of distances to other arrays ([Figure 2A,C](#f2){ref-type="fig"}). Additionally, the gene-level signal intensity distribution of CTRL3 was lower than that of other arrays and was flagged by arrayQualityMetrics's Kolmogorov--Smirnov-based outlier detection module ([Figure 2E,G](#f2){ref-type="fig"}). Given the magnitude of the difference between these two arrays and the other arrays, we removed these two arrays from the data set and reprocessed the remaining 16 samples ([Figure 2B,D,F,H](#f2){ref-type="fig"}). With this reduced data set, ARM7 was flagged as an outlier based on its sum of distances to other arrays ([Figure 2B,D](#f2){ref-type="fig"}). However, as the magnitude of this difference was marginal, we retained this sample in the data set. After CTRL3 and CTRL9 were removed, the p value for age between the two groups was 0.70.

![Overview of bioinformatics pipeline. Software is shown in the upper left corner of the boxes while the analytic process is indicated in the center of the boxes.](mv-v19-2274-f1){#f1}

![Quality control plots generated by arrayQualityMetrics before and after removal of CTRL3 and CTRL9. **A** and **B** are a false color heatmaps indicating the distances between arrays, computed as the absolute mean distance between the data. **C** and **D** indicate the sum of distances computed for **A** and **B**. For **C** the outlier threshold was 7.14 (vertical bar), and for D the outlier threshold was 5.79 (vertical bar). When analyzing all 18 samples, both CTRL3 and CTRL9 were flagged as exceeding the outlier threshold (**A** and **C**). When CTRL3 and CTRL9 were omitted, only ARM7 exceeded the threshold (**D**). **E** and **F** are boxplots of the gene-level signal intensity distribution across the arrays. For **E** and **F**, the Kolmogorov-Smirnov statistic K~a~ was calculated based on the distanced between each individual array and the pooled distribution of all arrays. **G** and **H** show K~a~ for each array with outlier thresholds (vertical bars) of 0.0509 and 0.049, respectively. Only CTRL3 was flagged by this metric (**G**).](mv-v19-2274-f2){#f2}

Differentially expressed genes
------------------------------

AltAnalyze mapped the exon array probesets to 42,187 unique Ensembl identifiers. To reduce false positive observations, we filtered this set by selecting only protein coding genes with mean log~2~ expression greater than or equal to the median expression of all protein-coding genes (7.11; [Figure 3](#f3){ref-type="fig"}), which resulted in 10,286 genes. We found 75 genes differentially expressed in AMD compared to controls (at least 50% difference in expression; moderated *t* test raw p value \<0.01; [Table 2](#t2){ref-type="table"}; [Figure 4](#f4){ref-type="fig"}). None of the genes were significantly differentially expressed after FDR correction (adj. p value \<0.1). We submitted the 52 downregulated genes and the 23 upregulated genes to DAVID for annotation. Of genes upregulated in early AMD, three genes (*FADS1, FADS2, PTPLA*) were identified as implicated in biosynthesis of unsaturated fatty acids (fold enrichment = 86.68; Benjamini corrected p value = 0.0052). Of genes downregulated in early AMD, 28 terms were significantly enriched (fold enrichment from 2 to 128; Benjamini-corrected p value \<0.01). These terms were associated with vision, sensory perception, and the plasma membrane. No transcripts flagged by AltAnalyze as putative splicing events appeared to be alternatively spliced upon close visual inspection of the probeset data in DomainGraph.

![Distribution of mean expression before median thresholding. Mean expression is log~2~ of gene-level signal intensity. The median indicated by the red line.](mv-v19-2274-f3){#f3}

###### Differentially expressed genes in early AMD versus control samples.

  Ensembl ID        Symbol           Mean AMD   Mean Control   Fold change   Raw p value   FDR adj. P value   Name
  ----------------- ---------------- ---------- -------------- ------------- ------------- ------------------ -----------------------------------------------------------------------------------------------------------
  ENSG00000138207   RBP4             9.01       7.92           2.12          0.0089        0.4149             retinol binding protein 4, plasma
  ENSG00000198759   EGFL6            7.78       6.77           2.01          0.0089        0.4149             EGF-like-domain, multiple 6
  ENSG00000158201   ABHD3            8.01       7.13           1.84          0.0044        0.3607             abhydrolase domain containing 3
  ENSG00000186480   INSIG1           9.25       8.44           1.76          0.0024        0.3582             insulin induced gene 1
  ENSG00000112972   HMGCS1           8.39       7.58           1.76          0.0095        0.4149             3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble)
  ENSG00000116791   CRYZ             9.20       8.39           1.75          0.0002        0.2057             crystallin, zeta (quinone reductase)
  ENSG00000135324   MRAP2            7.41       6.61           1.75          0.0006        0.2515             melanocortin 2 receptor accessory protein 2
  ENSG00000165124   SVEP1            8.16       7.37           1.74          0.0052        0.3792             sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1
  ENSG00000149485   FADS1            9.22       8.43           1.73          0.0035        0.3582             fatty acid desaturase 1
  ENSG00000112394   SLC16A10         7.43       6.67           1.70          0.0001        0.1976             solute carrier family 16, member 10 (aromatic amino acid transporter)
  ENSG00000109452   INPP4B           7.41       6.66           1.69          0.0031        0.3582             inositol polyphosphate-4-phosphatase, type II, 105 kDa
  ENSG00000091137   SLC26A4          7.80       7.04           1.69          0.0030        0.3582             solute carrier family 26, member 4
  ENSG00000134824   FADS2            9.08       8.34           1.67          0.0089        0.4149             fatty acid desaturase 2
  ENSG00000153790   C7orf31          8.06       7.32           1.67          0.0089        0.4149             chromosome 7 open reading frame 31
  ENSG00000251606   CTD-2215E18.1    8.28       7.55           1.66          0.0006        0.2515             Uncharacterized protein
  ENSG00000178896   EXOSC4           9.03       8.32           1.63          0.0039        0.3582             exosome component 4
  ENSG00000125931   CITED1           8.14       7.47           1.60          0.0013        0.3582             Cbp/p300-interacting transactivator, with Glu/Asp-rich C-terminal domain, 1
  ENSG00000184270   HIST2H2AB        8.04       7.41           1.55          0.0034        0.3582             histone cluster 2, H2ab
  ENSG00000121316   PLBD1            7.40       6.77           1.54          0.0001        0.1976             phospholipase B domain containing 1
  ENSG00000134202   GSTM3            8.04       7.42           1.53          0.0095        0.4149             glutathione S-transferase mu 3 (brain)
  ENSG00000165996   PTPLA            7.81       7.21           1.51          0.0000        0.1157             protein tyrosine phosphatase-like (proline instead of catalytic arginine), member A
  ENSG00000147459   DOCK5            7.25       6.65           1.51          0.0062        0.4088             dedicator of cytokinesis 5
  ENSG00000169084   DHRSX            7.68       7.09           1.51          0.0035        0.3582             dehydrogenase/reductase (SDR family) X-linked
  ENSG00000070961   ATP2B1           7.75       8.37           −1.53         0.0041        0.3582             ATPase, Ca^2+^ transporting, plasma membrane 1
  ENSG00000186260   MKL2             8.50       9.12           −1.54         0.0038        0.3582             MKL/myocardin-like 2
  ENSG00000125834   STK35            7.66       8.29           −1.54         0.0057        0.4062             serine/threonine kinase 35
  ENSG00000155749   ALS2CR12         6.77       7.39           −1.54         0.0004        0.2281             amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 12
  ENSG00000115350   POLE4            8.41       9.04           −1.55         0.0028        0.3582             polymerase (DNA-directed), epsilon 4 (p12 subunit)
  ENSG00000130559   CAMSAP1          7.34       7.98           −1.56         0.0028        0.3582             calmodulin regulated spectrin-associated protein 1
  ENSG00000132932   ATP8A2           6.46       7.13           −1.59         0.0030        0.3582             ATPase, aminophospholipid transporter, class I, type 8A, member 2
  ENSG00000181004   BBS12            7.07       7.75           −1.60         0.0098        0.4191             Bardet-Biedl syndrome 12
  ENSG00000149294   NCAM1            7.06       7.74           −1.60         0.0068        0.4149             neural cell adhesion molecule 1
  ENSG00000254528   RP11--728F11.4   7.98       8.67           −1.62         0.0018        0.3582             
  ENSG00000156194   PPEF2            7.19       7.89           −1.63         0.0024        0.3582             protein phosphatase, EF-hand calcium binding domain 2
  ENSG00000132026   RTBDN            6.52       7.25           −1.66         0.0032        0.3582             retbindin
  ENSG00000080511   RDH8             6.82       7.56           −1.66         0.0046        0.3607             retinol dehydrogenase 8 (all-trans)
  ENSG00000139220   PPFIA2           6.46       7.21           −1.68         0.0043        0.3582             protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 2
  ENSG00000082126   MPP4             7.27       8.02           −1.68         0.0088        0.4149             membrane protein, palmitoylated 4 (MAGUK p55 subfamily member 4)
  ENSG00000153944   MSI2             6.61       7.36           −1.68         0.0064        0.4141             musashi homolog 2 (Drosophila)
  ENSG00000239474   KBTBD10          7.54       8.30           −1.69         0.0025        0.3582             kelch repeat and BTB (POZ) domain containing 10
  ENSG00000131711   MAP1B            8.24       9.04           −1.74         0.0002        0.2057             microtubule-associated protein 1B
  ENSG00000102755   FLT1             9.15       9.97           −1.76         0.0059        0.4088             fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
  ENSG00000172519   OR10H5           6.51       7.33           −1.77         0.0011        0.3582             olfactory receptor, family 10, subfamily H, member 5
  ENSG00000059804   SLC2A3           7.88       8.77           −1.86         0.0003        0.2094             solute carrier family 2 (facilitated glucose transporter), member 3
  ENSG00000128052   KDR              8.08       8.99           −1.89         0.0015        0.3582             kinase insert domain receptor (a type III receptor tyrosine kinase)
  ENSG00000198515   CNGA1            8.87       9.90           −2.05         0.0005        0.2515             cyclic nucleotide gated channel alpha 1
  ENSG00000108370   RGS9             6.12       7.19           −2.10         0.0059        0.4088             regulator of G-protein signaling 9
  ENSG00000074621   SLC24A1          6.62       7.71           −2.13         0.0062        0.4088             solute carrier family 24 (sodium/potassium/calcium exchanger), member 1
  ENSG00000143995   MEIS1            7.49       8.59           −2.14         0.0000        0.1172             Meis homeobox 1
  ENSG00000149489   ROM1             7.80       8.94           −2.20         0.0036        0.3582             retinal outer segment membrane protein 1
  ENSG00000146350   C6orf170         6.09       7.26           −2.25         0.0001        0.2057             chromosome 6 open reading frame 170
  ENSG00000114279   FGF12            6.20       7.38           −2.27         0.0004        0.2281             fibroblast growth factor 12
  ENSG00000134183   GNAT2            6.85       8.08           −2.35         0.0036        0.3582             guanine nucleotide binding protein (G protein), alpha transducing activity polypeptide 2
  ENSG00000158445   KCNB1            6.13       7.37           −2.37         0.0047        0.3608             potassium voltage-gated channel, Shab-related subfamily, member 1
  ENSG00000118473   SGIP1            7.24       8.50           −2.38         0.0004        0.2281             SH3-domain GRB2-like (endophilin) interacting protein 1
  ENSG00000182985   CADM1            7.50       8.86           −2.58         0.0047        0.3608             cell adhesion molecule 1
  ENSG00000078018   MAP2             7.25       8.63           −2.60         0.0016        0.3582             microtubule-associated protein 2
  ENSG00000205683   DPF3             5.87       7.26           −2.62         0.0012        0.3582             D4, zinc and double PHD fingers, family 3
  ENSG00000047617   ANO2             6.73       8.16           −2.70         0.0043        0.3582             anoctamin 2
  ENSG00000158234   FAIM             6.41       7.96           −2.92         0.0020        0.3582             Fas apoptotic inhibitory molecule
  ENSG00000118402   ELOVL4           6.78       8.35           −2.97         0.0039        0.3582             ELOVL fatty acid elongase 4
  ENSG00000111837   MAK              6.18       7.76           −3.00         0.0020        0.3582             male germ cell-associated kinase
  ENSG00000203756   C6orf191         5.94       7.56           −3.07         0.0092        0.4149             chromosome 6 open reading frame 191
  ENSG00000114349   GNAT1            5.42       7.12           −3.24         0.0034        0.3582             guanine nucleotide binding protein (G protein), alpha transducing activity polypeptide 1
  ENSG00000100362   PVALB            6.18       7.88           −3.26         0.0084        0.4149             parvalbumin
  ENSG00000152578   GRIA4            5.84       7.55           −3.28         0.0031        0.3582             glutamate receptor, ionotrophic, AMPA 4
  ENSG00000132639   SNAP25           6.20       7.96           −3.38         0.0087        0.4149             synaptosomal-associated protein, 25 kDa
  ENSG00000148798   INA              5.36       7.17           −3.49         0.0074        0.4149             internexin neuronal intermediate filament protein, alpha
  ENSG00000130561   SAG              6.03       7.84           −3.51         0.0049        0.3688             S-antigen; retina and pineal gland (arrestin)
  ENSG00000112619   PRPH2            6.61       8.50           −3.73         0.0014        0.3582             peripherin 2 (retinal degeneration, slow)
  ENSG00000116703   PDC              5.93       7.86           −3.83         0.0096        0.4149             phosducin
  ENSG00000163914   RHO              7.26       9.23           −3.93         0.0051        0.3754             rhodopsin
  ENSG00000132915   PDE6A            5.87       7.88           −4.02         0.0045        0.3607             phosphodiesterase 6A, cGMP-specific, rod, alpha
  ENSG00000185518   SV2B             5.43       7.60           −4.50         0.0045        0.3607             synaptic vesicle glycoprotein 2B
  ENSG00000112706   IMPG1            5.29       7.50           −4.62         0.0060        0.4088             interphotoreceptor matrix proteoglycan 1

Genes were filtered based on at least 50% fold change between AMD and control and raw p value \<0.01.

![Heatmap of differentially expressed genes shown in [Table 2](#t2){ref-type="table"}. Dark shading indicates low expression; light shading indicates high expression.](mv-v19-2274-f4){#f4}

Comparison with previous studies
--------------------------------

Genome-wide association studies have identified several genes harboring polymorphisms associated with AMD. We compiled a list of these genes and examined their expression levels in our data set ([Table 3](#t3){ref-type="table"}; [Figure 5](#f5){ref-type="fig"}). Some genes (e.g., *ADAMTS9, APOE, ARMS2, B3GALT1, CCR3, CETP, CFHR2, CFHR3, COL10A1, DDR1, LIPC, RAD51B, TGFBR1, TLR3*) did not meet our filtering criteria (i.e., mean expression in AMD or control groups \> median expression of all protein coding genes). Of the genes previously associated with AMD, none were differentially expressed (raw p value \<0.01).

###### Genes previously associated with AMD by genetic studies.

  Ensembl ID        Symbol      Mean AMD   Mean Control   Fold change   Raw p value   FDR adj. P value   Name
  ----------------- ----------- ---------- -------------- ------------- ------------- ------------------ --------------------------------------------------------------------------------------------------
  ENSG00000100156   SLC16A8     8.26       7.88           1.31          0.0129        0.4358             solute carrier family 16, member 8 (monocarboxylic acid transporter 3) \[[@r43]\]
  ENSG00000166278   C2          7.49       7.19           1.24          0.1434        0.6643             complement component 2 \[[@r43],[@r45],[@r46]\]
  ENSG00000125730   C3          8.80       8.55           1.19          0.1226        0.6470             complement component 3 \[[@r40],[@r47]-[@r49]\]
  ENSG00000000971   CFH         9.64       9.43           1.16          0.2662        0.7440             complement factor H \[[@r41],[@r50]-[@r52]\]
  ENSG00000100234   TIMP3       11.37      11.22          1.11          0.3122        0.7823             TIMP metallopeptidase inhibitor 3 \[[@r40],[@r49],[@r53],[@r54]\]
  ENSG00000243649   CFB         7.93       7.81           1.09          0.4199        0.8396             complement factor B \[[@r43],[@r45],[@r46]\]
  ENSG00000205403   CFI         8.93       8.84           1.07          0.6688        0.9296             complement factor I \[[@r43],[@r55]\]
  ENSG00000225830   ERCC6       7.34       7.29           1.03          0.7487        0.9492             excision repair cross-complementing rodent repair deficiency, complementation group 6 \[[@r56]\]
  ENSG00000137331   IER3        7.72       7.67           1.03          0.8162        0.9636             immediate early response 3 \[[@r43]\]
  ENSG00000168386   FILIP1L     8.14       8.17           −1.02         0.8496        0.9718             filamin A interacting protein 1-like \[[@r43]\]
  ENSG00000144810   COL8A1      9.15       9.20           −1.04         0.7052        0.9370             collagen, type VIII, alpha 1 \[[@r43],[@r57]\]
  ENSG00000166033   HTRA1       8.36       8.50           −1.10         0.4118        0.8344             HtrA serine peptidase 1 \[[@r58]-[@r60]\]
  ENSG00000104689   TNFRSF10A   6.88       7.12           −1.18         0.0136        0.4398             tumor necrosis factor receptor superfamily, member 10a \[[@r43],[@r61]\]
  ENSG00000112715   VEGFA       7.11       7.36           −1.19         0.0735        0.5904             vascular endothelial growth factor A \[[@r12],[@r62]\]
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Analysis of genes associated with either RPE or vascular endothelium
--------------------------------------------------------------------

We next evaluated genes with cell-type-specific expression in either the RPE or endothelium. For RPE genes, we took the top 35 genes identified as highly expressed in the RPE versus the retina and choroid in the recent manuscript by Booij and colleagues \[[@r33]\]. We added *SERPINF1* (PEDF), another marker of RPE, to this set \[[@r34]\]. Of these, 28 mapped to Ensembl IDs in our filtered set and were included for analysis. Thirteen RPE-expressed genes showed between 12% and 72% increased expression (raw p value \<0.1; [Table 4](#t4){ref-type="table"}; [Figure 6](#f6){ref-type="fig"}).

###### Genes highly expressed in the RPE.

  Ensembl ID        Symbol     Mean AMD   Mean Control   Fold change   Raw p value   FDR adj. P value   Name
  ----------------- ---------- ---------- -------------- ------------- ------------- ------------------ -------------------------------------------------------------------------------------------------------------------
  ENSG00000147003   TMEM27     9.25       8.47           1.72          0.0130        0.4358             transmembrane protein 27 \[[@r33]\]
  ENSG00000084453   SLCO1A2    7.82       7.06           1.69          0.0232        0.4779             solute carrier organic anion transporter family, member 1A2 \[[@r33]\]
  ENSG00000150656   CNDP1      8.76       8.04           1.64          0.0813        0.5984             carnosine dipeptidase 1 (metallopeptidase M20 family) \[[@r33]\]
  ENSG00000101144   BMP7       7.29       6.64           1.57          0.0361        0.5074             bone morphogenetic protein 7 \[[@r33]\]
  ENSG00000105855   ITGB8      9.46       8.86           1.52          0.0627        0.5757             integrin, beta 8 \[[@r33]\]
  ENSG00000157193   LRP8       9.09       8.52           1.48          0.0333        0.4942             low density lipoprotein receptor-related protein 8, apolipoprotein e receptor \[[@r33]\]
  ENSG00000139155   SLCO1C1    10.15      9.68           1.39          0.0425        0.5262             solute carrier organic anion transporter family, member 1C1 \[[@r33]\]
  ENSG00000122481   RWDD3      8.31       7.84           1.38          0.0942        0.6178             RWD domain containing 3 \[[@r33]\]
  ENSG00000136541   ERMN       9.28       8.83           1.36          0.1648        0.6759             ermin, ERM-like protein \[[@r33]\]
  ENSG00000167995   BEST1      9.29       8.84           1.36          0.0621        0.5736             bestrophin 1 \[[@r33]\]
  ENSG00000180287   PLD5       10.21      9.77           1.35          0.0695        0.5816             phospholipase D family, member 5 \[[@r33]\]
  ENSG00000170011   MYRIP      8.46       8.03           1.35          0.1063        0.6341             myosin VIIA and Rab interacting protein \[[@r33]\]
  ENSG00000187889   C1orf168   7.15       6.75           1.33          0.2653        0.7427             chromosome 1 open reading frame 168 \[[@r33]\]
  ENSG00000148482   SLC39A12   8.60       8.20           1.32          0.1679        0.6783             solute carrier family 39 (zinc transporter), member 12 \[[@r33]\]
  ENSG00000116745   RPE65      11.29      10.90          1.32          0.0376        0.5105             retinal pigment epithelium-specific protein 65 kDa \[[@r33]\]
  ENSG00000183715   OPCML      7.40       7.04           1.28          0.2173        0.7119             opioid binding protein/cell adhesion molecule-like \[[@r33]\]
  ENSG00000114115   RBP1       9.29       8.93           1.28          0.1930        0.6977             retinol binding protein 1, cellular \[[@r33]\]
  ENSG00000108231   LGI1       8.58       8.23           1.27          0.2161        0.7105             leucine-rich, glioma inactivated 1 \[[@r33]\]
  ENSG00000128578   FAM40B     9.07       8.73           1.26          0.3842        0.8192             family with sequence similarity 40, member B \[[@r33]\]
  ENSG00000159212   CLIC6      10.51      10.19          1.25          0.2284        0.7221             chloride intracellular channel 6 \[[@r33]\]
  ENSG00000141526   SLC16A3    7.97       7.67           1.23          0.0985        0.6231             solute carrier family 16, member 3 (monocarboxylic acid transporter 4) \[[@r33]\]
  ENSG00000121207   LRAT       10.84      10.57          1.21          0.2578        0.7374             lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase) \[[@r33]\]
  ENSG00000140522   RLBP1      9.18       8.94           1.18          0.2469        0.7340             retinaldehyde binding protein 1 \[[@r33]\]
  ENSG00000132386   SERPINF1   10.54      10.31          1.17          0.2352        0.7252             serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 \[[@r34]\]
  ENSG00000010379   SLC6A13    7.31       7.11           1.14          0.3584        0.8067             solute carrier family 6 (neurotransmitter transporter, GABA), member 13 \[[@r33]\]
  ENSG00000083067   TRPM3      11.43      11.25          1.13          0.3586        0.8067             transient receptor potential cation channel, subfamily M, member 3 \[[@r33]\]
  ENSG00000142611   PRDM16     7.28       7.12           1.12          0.0982        0.6231             PR domain containing 16 \[[@r33]\]
  ENSG00000139318   DUSP6      9.18       9.10           1.06          0.6565        0.9264             dual specificity phosphatase 6 \[[@r33]\]

Genes in this list were previously reported as highly expressed in RPE compared to retina and choroid \[[@r33]\] or known to be RPE-specific (i.e., SERPINF1) \[[@r34]\].
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As a proxy for choroidal endothelial cells, we compiled a list of 24 genes with known expression in the endothelium and compared the fold change between the AMD and control samples. Endothelium-associated genes were based on gene lists identified as specific to the endothelium \[[@r35]\] or from a literature search. Seven of these genes showed decreased expression in early AMD between 20% and 189% (raw p value \<0.1; [Table 5](#t5){ref-type="table"}; [Figure 7](#f7){ref-type="fig"}), which suggested decreased numbers of vascular endothelial cells in the choroid and/or dedifferentiation of extant endothelial cells. Thus, there appeared to be a trend toward increased expression of RPE-expressed genes and decreased expression of endothelium-expressed genes in eyes with early AMD.

###### Genes expressed in endothelial cells.

  Ensembl ID        Symbol   Mean AMD   Mean Control   Fold change   Raw p value   FDR adj. P value   Name
  ----------------- -------- ---------- -------------- ------------- ------------- ------------------ ---------------------------------------------------------------------------------------------------------------------
  ENSG00000115380   EFEMP1   10.25      10.05          1.15          0.3126        0.7823             EGF containing fibulin-like extracellular matrix protein 1 \[[@r35]\]
  ENSG00000152818   UTRN     9.66       9.50           1.12          0.2251        0.7199             utrophin \[[@r35]\]
  ENSG00000118523   CTGF     8.17       8.01           1.11          0.3471        0.8008             connective tissue growth factor \[[@r35]\]
  ENSG00000078401   EDN1     7.28       7.18           1.07          0.5917        0.9029             endothelin 1 \[[@r35]\]
  ENSG00000164035   EMCN     9.22       9.26           −1.02         0.9159        0.9858             endomucin \[[@r35]\]
  ENSG00000101000   PROCR    8.44       8.50           −1.04         0.6952        0.9347             protein C receptor, endothelial \[[@r35]\]
  ENSG00000111341   MGP      10.96      11.05          −1.06         0.3872        0.8200             matrix Gla protein \[[@r35]\]
  ENSG00000205542   TMSB4X   10.57      10.67          −1.07         0.5172        0.8821             thymosin beta 4, X-linked \[[@r35]\]
  ENSG00000174175   SELP     7.27       7.41           −1.10         0.6747        0.9312             selectin P (granule membrane protein 140 kDa, antigen CD62) \[[@r63],[@r64]\]
  ENSG00000108622   ICAM2    7.53       7.68           −1.11         0.1335        0.6557             intercellular adhesion molecule 2 \[[@r35]\]
  ENSG00000131471   AOC3     7.21       7.38           −1.12         0.2033        0.7008             amine oxidase, copper containing 3 (vascular adhesion protein 1) \[[@r65]\]
  ENSG00000249751   ECSCR    7.77       7.94           −1.12         0.1685        0.6783             endothelial cell-specific chemotaxis regulator \[[@r35]\]
  ENSG00000167434   CA4      7.52       7.72           −1.15         0.3435        0.7992             carbonic anhydrase IV \[[@r66]\]
  ENSG00000179776   CDH5     7.55       7.81           −1.20         0.0621        0.5736             cadherin 5, type 2 (vascular endothelium) \[[@r35]\]
  ENSG00000168497   SDPR     6.92       7.25           −1.26         0.0529        0.5567             serum deprivation response \[[@r35]\]
  ENSG00000003436   TFPI     7.65       8.01           −1.28         0.1613        0.6758             tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) \[[@r35]\]
  ENSG00000178726   THBD     7.41       7.82           −1.34         0.1061        0.6340             thrombomodulin \[[@r35]\]
  ENSG00000120156   TEK      7.40       7.83           −1.35         0.1085        0.6363             TEK tyrosine kinase, endothelial \[[@r67]\]
  ENSG00000106991   ENG      8.57       9.01           −1.35         0.1025        0.6275             endoglin \[[@r35]\]
  ENSG00000110799   VWF      9.34       9.87           −1.45         0.0680        0.5797             von Willebrand factor \[[@r35]\]
  ENSG00000138722   MMRN1    7.25       7.96           −1.64         0.0551        0.5579             multimerin 1 \[[@r35]\]
  ENSG00000091879   ANGPT2   6.94       7.72           −1.72         0.0420        0.5244             angiopoietin 2 \[[@r67]\]
  ENSG00000102755   FLT1     9.15       9.97           −1.76         0.0059        0.4088             fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) \[[@r35]\]
  ENSG00000128052   KDR      8.08       8.99           −1.89         0.0015        0.3582             kinase insert domain receptor (a type III receptor tyrosine kinase) \[[@r35]\]

Genes in this list were previously reported as associated with endothelial cells.
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To calculate the enrichment of the RPE and endothelium gene sets, we performed GSEA \[[@r29]\]. For each gene set, GSEA calculates (a) an enrichment score (ES) based on the rank distribution of individual genes within the set from among all unique genes symbols in our filtered set (n=10,286), (b) a normalized enrichment score (NES) that accounts for the size of the set, (c) a nominal p value based on phenotype permutation, e.g., AMD or control status of samples, and (d) an FDR *q* value to control for the gene set size and multiple hypothesis testing. GSEA suggests a greater trend for the overall enrichment of the endothelium-associated gene set in AMD samples (ES = --0.78; NES = --1.39; nominal p value=0.133; FDR *q* value = 0.08) than the enrichment of RPE-specific genes in the control samples (ES = 0.81; NES = 1.3; nom. P value = 0.167; FDR *q* value = 0.191). Since an FDR *q* value of less than 0.25 is considered significant for GSEA \[[@r29]\], these data suggest a significant decrease in endothelial cell transcripts.

Analysis of *CFH* risk genotypes
--------------------------------

Last, we reanalyzed the data set by stratifying based on genotypes at the rs1061170 SNP in *CFH* (11 high-risk, YH/HH samples; five low-risk, YY samples), independent of AMD affection status. The same filtering criteria were applied as in the previous analysis, retaining 10,288 protein-coding genes. Thirty-five genes were identified as differentially expressed (at least 50% difference in expression; moderated *t* test raw p value \<0.01; [Table 6](#t6){ref-type="table"}). None of the genes were significantly differentially expressed after FDR correction (p value \<0.1).

###### Differentially expressed genes high-risk CFH genotypes (YH/HH) versus low-risk CFH genotype (YY).

  Ensembl ID        Symbol    Mean AMD   Mean Control   Fold change   Raw p value   FDR adj. P value   Name
  ----------------- --------- ---------- -------------- ------------- ------------- ------------------ -----------------------------------------------------------------------------------
  ENSG00000127083   OMD       7.19       5.97           2.33          0.0047        0.8828             osteomodulin
  ENSG00000146374   RSPO3     8.03       6.88           2.21          0.0058        0.8828             R-spondin 3
  ENSG00000011465   DCN       8.86       7.72           2.19          0.0008        0.6616             decorin
  ENSG00000090104   RGS1      8.10       7.10           2.00          0.0076        0.8828             regulator of G-protein signaling 1
  ENSG00000186439   TRDN      8.04       7.08           1.95          0.0068        0.8828             triadin
  ENSG00000176971   FIBIN     8.87       7.98           1.86          0.0004        0.6215             fin bud initiation factor homolog (zebrafish)
  ENSG00000146233   CYP39A1   7.31       6.46           1.80          0.0065        0.8828             cytochrome P450, family 39, subfamily A, polypeptide 1
  ENSG00000196344   ADH7      7.66       6.94           1.65          0.0017        0.7811             alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide
  ENSG00000182230   FAM153B   7.23       6.54           1.61          0.0056        0.8828             family with sequence similarity 153, member B
  ENSG00000116667   C1orf21   10.29      9.65           1.56          0.0000        0.1533             chromosome 1 open reading frame 21
  ENSG00000121769   FABP3     7.48       6.85           1.55          0.0088        0.8828             fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)
  ENSG00000071189   SNX13     8.46       7.82           1.55          0.0020        0.7811             sorting nexin 13
  ENSG00000115607   IL18RAP   7.46       8.05           −1.50         0.0083        0.8828             interleukin 18 receptor accessory protein
  ENSG00000089157   RPLP0     7.00       7.59           −1.51         0.0029        0.7833             ribosomal protein, large, P0
  ENSG00000177076   ACER2     6.82       7.41           −1.51         0.0027        0.7833             alkaline ceramidase 2
  ENSG00000146592   CREB5     6.66       7.26           −1.51         0.0070        0.8828             cAMP responsive element binding protein 5
  ENSG00000182853   VMO1      6.58       7.18           −1.52         0.0051        0.8828             vitelline membrane outer layer 1 homolog (chicken)
  ENSG00000141753   IGFBP4    9.07       9.71           −1.56         0.0082        0.8828             insulin-like growth factor binding protein 4
  ENSG00000167772   ANGPTL4   7.66       8.32           −1.58         0.0003        0.6215             angiopoietin-like 4
  ENSG00000198959   TGM2      8.87       9.61           −1.68         0.0006        0.6616             transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)
  ENSG00000104332   SFRP1     6.96       7.77           −1.76         0.0067        0.8828             secreted frizzled-related protein 1
  ENSG00000113083   LOX       6.29       7.14           −1.80         0.0055        0.8828             lysyl oxidase
  ENSG00000167236   CCL23     7.10       8.00           −1.86         0.0066        0.8828             chemokine (C-C motif) ligand 23
  ENSG00000068366   ACSL4     7.33       8.33           −2.00         0.0028        0.7833             acyl-CoA synthetase long-chain family member 4
  ENSG00000138135   CH25H     6.20       7.21           −2.01         0.0057        0.8828             cholesterol 25-hydroxylase
  ENSG00000102265   TIMP1     10.09      11.11          −2.03         0.0035        0.8828             TIMP metallopeptidase inhibitor 1
  ENSG00000156804   FBXO32    6.83       7.96           −2.19         0.0000        0.1533             F-box protein 32
  ENSG00000179431   FJX1      8.10       9.28           −2.27         0.0008        0.6616             four jointed box 1 (Drosophila)
  ENSG00000163638   ADAMTS9   5.74       7.12           −2.61         0.0008        0.6616             ADAM metallopeptidase with thrombospondin type 1 motif, 9
  ENSG00000124102   PI3       6.40       7.79           −2.63         0.0006        0.6616             peptidase inhibitor 3, skin-derived
  ENSG00000205362   MT1A      8.34       9.75           −2.66         0.0082        0.8828             metallothionein 1A
  ENSG00000159167   STC1      9.09       10.62          −2.90         0.0027        0.7833             stanniocalcin 1
  ENSG00000064886   CHI3L2    6.20       7.83           −3.10         0.0070        0.8828             chitinase 3-like 2
  ENSG00000162992   NEUROD1   5.41       7.30           −3.69         0.0092        0.8828             neurogenic differentiation 1
  ENSG00000115602   IL1RL1    5.35       7.33           −3.93         0.0001        0.3640             interleukin 1 receptor-like 1

DAVID analysis of the 12 genes with increased expression in the high-risk genotype revealed no significantly enriched terms (with Benjamini corrected p value \<0.01). In the DAVID analysis of the 23 genes with lower expression in the high-risk genotype, DAVID identified eight terms with significant enrichment (fold enrichment from 3 to 8; Benjamini corrected p value \<0.01). These terms were associated with extracellular secretion, signal peptides, and disulfide bonds.

Discussion
==========

AMD is a complex disease that shows altered function and viability of photoreceptor cells, RPE, and choriocapillaris endothelial cells. Although our understanding of the genetics of AMD has progressed in the last decade, many basic questions about the pathogenesis of this disease remain. In the current study, we evaluated gene expression at the exon level in AMD and control eyes and found a loss of transcripts expressed by choroidal endothelial cells.

Limitations of the current study include small sample size (due to stringent inclusion criteria) and the lack of strong signatures of differential expression between the case and control samples, obviating validation of single genes. Increased sample size may reveal some genes with a small difference between the cases and controls, which remain significant after multiple hypothesis testing. However, this is unlikely. Previous analysis of AMD-affected tissues with microarray technologies required the use of non-standard methods to identify altered gene expression (expression correlation between two data sets with p\<0.1 and 25% fold change) \[[@r15]\] or the use of sensitive clustering algorithms to identify patterns across many AMD grades simultaneously \[[@r14]\]. At the tissue level in our data set, the apparent trends among the RPE and endothelial genes (overall direction of fold change and p\<0.1) are supported by the GSEA results. These gene set-level changes are small in our samples.

Cross-contamination by photoreceptor-specific transcripts
---------------------------------------------------------

We observed an elevation of select photoreceptor-specific genes (i.e., *RHO, PDC*) across all control samples compared to the AMD-affected samples, particularly noticeable in CTRL4 and CTRL5. High expression of retinal transcripts is commonly reported in gene expression studies of the RPE and choroid \[[@r14],[@r36],[@r37]\], and various strategies have been taken to deal with cross-contamination (e.g., laser capture microdissection \[[@r33]\], flagging genes with high expression in one tissue that appear in another tissue \[[@r14]\]). Cross-contamination is not surprising, as photoreceptor cell outer segments are partially interdigitated and ensheathed by the apical microvilli of the RPE and supported by the interphotoreceptor matrix \[[@r38]\]. Although most photoreceptor cell transcripts are expected to be within the outer nuclear layer and inner segments, Van Soest and colleagues suggest that these transcripts may be present at the interface between the photoreceptor outer segments and apical RPE \[[@r37]\]. The photoreceptor cell-specific gene expression we observed could be an artifact of mechanical separation or a stochastic individual variation in adhesion, and this random event might have occurred to a higher degree in the control eyes. However, we hypothesize that the pattern of elevated retinal contamination in the controls, which was absent from AMD cases, may be due to decreased adhesion of the retina to the RPE in the AMD samples compared to the controls. Although adhesion between the neural retina and the RPE has been examined in primates \[[@r39]\], to our knowledge this has not been investigated in the context of early AMD. Alternatively, if neural retina components are uniformly present in all samples, then the decreased expression of retina-specific genes in the AMD samples could indicate that expression within photoreceptors is decreased even at the earliest stages of AMD.

Intriguingly, genes with lower expression in AMD than in controls included *KDR* and *FLT1*, known VEGF receptors. Hierarchical clustering reveals that these genes do not segregate with the neural retina-specific genes and that expression of this sub-cluster of genes is consistent across controls and is not affected by CTRL4 and CTRL5 ([Figure 1](#f1){ref-type="fig"}).

Loss of endothelial-specific gene expression
--------------------------------------------

Our group has previously shown that the density of microvasculature decreases as the volume of sub-RPE drusen increases \[[@r9]\]. Similarly, studies of blood flow in eyes with drusen show susceptibility of the choroidal vasculature to degenerative changes in AMD \[[@r11]\]. In elegant whole mount studies of eyes with advanced AMD, McLeod and colleagues found a linear relationship between the RPE and choriocapillaris, with the loss of either layer affecting the integrity of the other \[[@r10]\]. From these studies, with a sample size similar to that in the current report, the authors concluded that RPE loss precedes endothelium loss in GA, whereas endothelium loss precedes RPE loss in CNV \[[@r10]\]. Our data indicate that gene expression of endothelium-related genes decreases in early AMD before any atrophy or neovascular change develops.

Our results are also consistent with state-of-the-art proteomics studies of Bruch's membrane--choroid preparations, in which the authors found the endothelial cell proteins von Willebrand factor (VWF) and carbonic anhydrase 4 (CA4) are reduced in early and mid-stage AMD and advanced dry AMD, respectively \[[@r40]\]. The same authors showed no loss of RPE proteins RPE65 and CRALBP (*RLBP1*). In fact, the levels of these proteins were elevated in Bruch's membrane, consistent with our findings at the mRNA level. Taken together, these studies suggest loss or dedifferentiation of choroidal endothelial cells before loss of the RPE in eyes with AMD. In addition, expression of the choroidal endothelial genes *ICAM1, SELE,* and *PLVAP* was decreased in some AMD classes in the report by Newman et al. (supplemental data) \[[@r14]\].

Decreased expression of *ADAMTS9* in samples with high AMD risk *CFH* genotype
------------------------------------------------------------------------------

Eyes with high-risk CFH genotypes were also assessed for gene expression changes. We previously found increased membrane attack complex formation in eyes homozygous for the high-risk allele \[[@r41]\], and complement activation may affect gene expression in nearby cells. Although not significant after multiple hypothesis testing correction, expression of *ADAMTS9* transcripts was lower in samples with high-risk CFH genotypes than in samples with the low-risk genotype. This gene is a member of the ADAMTS (a disintegrin-like and metalloprotease domain with thrombospondin type I motifs) protein family with the ability to cleave aggrecan and versican \[[@r42]\]. Recently a SNP (rs6795735) located 32.5 kb upstream of the *ADAMTS9* transcription start site was associated with increased risk of AMD in a meta-analysis of genome-wide association (GWA) data \[[@r43]\]. ADAMTS9 is expressed in ARPE-19 cells \[[@r44]\] and several types of microvascular endothelial cells \[[@r42]\], although to our knowledge localization of ADAMTS9 has not been examined in human RPE and choroid samples. In microvascular endothelial cells, ADAMTS9 suppresses angiogenesis, albeit not via sequestration of VEGF165 \[[@r42]\]. Further experimentation is necessary to elucidate the relationship between CFH activity and ADAMTS9 function in early AMD.

In conclusion, we performed microarray analysis of human donor maculas and found early loss of choriocapillaris endothelial cell markers in early AMD, with preservation of RPE cell transcripts. These results have potential importance for therapy. Recently, the replacement of RPE cells in AMD has been contemplated as a treatment for AMD. These studies, as well as proteomic \[[@r40]\], anatomic \[[@r9],[@r10]\], and clinical \[[@r11]\] studies, strongly suggest caution in this type of approach, since transplanting healthy RPE into a macula with a degenerated choriocapillaris may be fruitless. In addition to replacing photoreceptor cells and RPE, strategies for replacing lost choriocapillaris are necessary to fully restore function in AMD.
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